is berberine a natural glp 1 Patch (Natural GLP-1) by PatchAid Feelgood Company - Berberine -

Weight loss, achieved through dietary measures or bariatric surgery, has been shown to benefit HS in many patients, but sustaining meaningful reductions remains challenging in clinical practice

Improve Documentation and Chart Review Processes Comprehensive documentation helps demonstrate that patient care decisions are supported by appropriate evaluations and clinical judgment

"This is the first time I've opened up about this." These medications, which go by brand names like Ozempic, Wegovy and Mounjaro, have changed the game for weight management, especially for people who struggle with metabolic resistance or have conditions like type 2 diabetes, explains Giselle Prado-Wright, MD, MBA, medical director at Exert BodySculpt

doi: 10.2527/jas.2010-2938

Study Population : 1,961 adults without diabetes Average age: 46 years Average baseline BMI: 37.9 Average baseline weight: 231.3 pounds 74.1% female, 25.9% male 76.6% White, 11.6% Black, 7.0% Asian, 4.8% Other Intervention : Semaglutide 2.4 mg subcutaneously once weekly (n=1,306) Placebo subcutaneously once weekly (n=655) Both groups: Individual counseling sessions every 4 weeks promoting 500-calorie deficit and 150 minutes/week physical activity Duration : 68 weeks Primary Outcome - Mean Percentage Weight Loss : Semaglutide: -14.9% (95% CI: -15.3 to -14.5) Placebo: -2.4% (95% CI: -3.0 to -1.8) Difference: -12.4 percentage points (p0.001) Secondary Outcomes - Categorical Weight Loss : 5% weight loss : 86.4% semaglutide vs 31.5% placebo 10% weight loss : 69.1% semaglutide vs 12.0% placebo 15% weight loss : 50.5% semaglutide vs 4.9% placebo 20% weight loss : 32.0% semaglutide vs 1.7% placebo Trial Completion Rates : Semaglutide: 81.7% completed 68 weeks Placebo: 82.0% completed 68 weeks High completion rates suggest good tolerability and participant satisfaction Safety Data : Gastrointestinal adverse events: 74.2% semaglutide vs 47.9% placebo Serious adverse events: 9.8% semaglutide vs 6.4% placebo Discontinuation due to adverse events: 7.0% semaglutide vs 3.1% placebo STEP 2: Diabetes Population Trial Citation : Davies M, et al